| アブストラクト | BACKGROUND: Previous reports indicated still low implementation rates of multigene testing for advanced non-small cell lung cancer (NSCLC) in Japan. METHODS: This is a retrospective study launched at the initiative of lung cancer patients. Patients with stage IV NSCLC from January 2019 to December 2022 were investigated for testing of 8 actionable oncogenic drivers with targeted therapies available as of 2022. RESULTS: A total of 15,719 patients were included. Between 2019 and 2022, the percentage of patients who were not tested for any actionable oncogenic drivers remained the same, ranging from 21.5% to 33.1%. However, since late 2021, the percentage of patients tested for five or more actionable oncogenic drivers has increased. Across hospital categories and regions, the number of actionable oncogenic drivers tested was similar. CONCLUSIONS: This patient-initiated national survey in Japan reveals the recent nationwide increase in testing rates for actionable oncogenic drivers in Advanced NSCLC. |
|---|
| ジャーナル名 | Cancer medicine |
|---|
| Pubmed追加日 | 2024/11/4 |
|---|
| 投稿者 | Ikeda, Satoshi; Hasegawa, Kazuo; Kachi, Kenta; Yanagisawa, Akihiro; Kawakami, Sachiko; Hamasaki, Shinsuke; Watanabe, Sachiko; Yoshikawa, Aki; Takahama, Takayuki; Nakagawa, Kazuhiko |
|---|
| 組織名 | Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory;Center, Yokohama, Japan.;Japan Lung Cancer Alliance, Yokohama, Japan.;General Incorporated Association Alliance for Lung Cancer, Yokohama, Japan.;Global Health Consulting Japan, Tokyo, Japan.;Department of Medical Oncology, Kindai University Faculty of Medicine,;Osakasayama, Japan. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/39494523/ |
|---|
